383 related articles for article (PubMed ID: 19507806)
21. Dose proportionality and pharmacokinetics of extended-release (OROS®) hydromorphone: a phase 1, open-label, randomized, crossover study in healthy Taiwanese subjects.
Vandenbossche J; Richards HM; Lu CC; Richarz U
Int J Clin Pharmacol Ther; 2014 Mar; 52(3):217-26. PubMed ID: 24472398
[TBL] [Abstract][Full Text] [Related]
22. Open-label study on the long-term efficacy, safety, and impact on quality of life of OROS hydromorphone ER in patients with chronic low back pain.
Wallace M; Thipphawong J
Pain Med; 2010 Oct; 11(10):1477-88. PubMed ID: 21199302
[TBL] [Abstract][Full Text] [Related]
23. Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain.
Weinstein SM; Shi M; Buckley BJ; Kwarcinski MA
Clin Ther; 2006 Jan; 28(1):86-98. PubMed ID: 16490582
[TBL] [Abstract][Full Text] [Related]
24. A prospective, open-label, multicenter study of the clinical efficacy of extended-release hydromorphone in treating cancer pain inadequately controlled by other analgesics.
Han HS; Lee KH; Lee KH; Ryu JS; Kim YC; Park SW; Oh HS; Park KT; Kwon JH; Lee PB; Lee WS; Kim YS; Ahn JB; Jeon SW; Lee SY; Seol YM; Kang JH; Yuh YJ; Oh SY; Kim SR; Ahn JS
Support Care Cancer; 2014 Mar; 22(3):741-50. PubMed ID: 24203087
[TBL] [Abstract][Full Text] [Related]
25. Once-daily OROS hydromorphone ER compared with placebo in opioid-tolerant patients with chronic low back pain.
Hale M; Khan A; Kutch M; Li S
Curr Med Res Opin; 2010 Jun; 26(6):1505-18. PubMed ID: 20429852
[TBL] [Abstract][Full Text] [Related]
26. Oral hydromorphone extended-release.
Guay DR
Consult Pharm; 2010 Dec; 25(12):816-28. PubMed ID: 21172762
[TBL] [Abstract][Full Text] [Related]
27. Comparative effects of morning vs. evening dosing of extended-release hydromorphone on sleep physiology in patients with low back pain: a pilot study.
Webster LR; Smith MD; Mackin S; Iverson M
Pain Med; 2015 Mar; 16(3):460-71. PubMed ID: 25279807
[TBL] [Abstract][Full Text] [Related]
28. [Oral osmotic hydromorphone (OROS) in patients with chronic severe pain due to osteoarthritis under daily routine conditions].
Müller-Schwefe GH; Blimke B; Hesselbarth S; Giesecke T
MMW Fortschr Med; 2014 Apr; 156 Suppl 1():23-9. PubMed ID: 24930329
[TBL] [Abstract][Full Text] [Related]
29. Once-Daily OROS Hydromorphone for Management of Cancer Pain: an Open-Label, Multi-Center, Non-Interventional Study.
Park CK; Kang HW; Oh IJ; Kim YC; Kim YK; Na KJ; Ahn SJ; Kim TO; Choi YJ; Song GA; Lee MK
J Korean Med Sci; 2016 Dec; 31(12):1914-1921. PubMed ID: 27822929
[TBL] [Abstract][Full Text] [Related]
30. [Pharmacotherapy of chronic, non-tumour related pain. Efficacy, tolerability and patient benefit of an oral osmotic system with hydromorphone].
Sabatowski R; Giesecke T
MMW Fortschr Med; 2007 Sep; 149 Suppl 3():119-24. PubMed ID: 17955789
[TBL] [Abstract][Full Text] [Related]
31. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
32. Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study.
Yu S; Shen W; Yu L; Hou Y; Han J; Richards HM
J Pain; 2014 Aug; 15(8):835-44. PubMed ID: 24846822
[TBL] [Abstract][Full Text] [Related]
33. Use of OROS® hydromorphone in the treatment of osteoarthritis and osteoporosis: A pooled analysis of three non-interventional studies focusing on different starting doses.
Ringe JD; Schäfer S; Wimmer AM; Giesecke T
Wien Klin Wochenschr; 2012 Jan; 124(1-2):25-31. PubMed ID: 22045112
[TBL] [Abstract][Full Text] [Related]
34. The role of OROS hydromorphone in the management of cancer pain.
Gardner-Nix J; Mercadante S
Pain Pract; 2010; 10(1):72-7. PubMed ID: 19863749
[TBL] [Abstract][Full Text] [Related]
35. Long-term efficacy of OROS® hydromorphone combined with pregabalin for chronic non-cancer neuropathic pain.
Dauri M; Lazzari M; Casali M; Tufaro G; Sabato E; Sabato AF
Clin Drug Investig; 2014 May; 34(5):309-16. PubMed ID: 24567278
[TBL] [Abstract][Full Text] [Related]
36. Six-month, open-label study of hydrocodone extended release formulated with abuse-deterrence technology: Safety, maintenance of analgesia, and abuse potential.
Hale ME; Ma Y; Malamut R
J Opioid Manag; 2016; 12(2):139-47. PubMed ID: 27194199
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of a new once daily hydromorphone formulation in comparison with twice daily administration in chronic pain: a randomized, double-blind, cross-over study.
Nold GE; Maritz MA; Schwittay A; Schumann C; Rey H
Curr Med Res Opin; 2016 May; 32(5):869-77. PubMed ID: 26824884
[TBL] [Abstract][Full Text] [Related]
38. A multicenter, 12-month, open-label, single-arm safety study of oxycodone-hydrochloride/naltrexone-hydrochloride extended-release capsules (ALO-02) in patients with moderate-to-severe chronic noncancer pain.
Arora S; Setnik B; Michael D; Hudson JD; Clemmer R; Meisner P; Pixton GC; Goli V; Sommerville KW
J Opioid Manag; 2014; 10(6):423-36. PubMed ID: 25531960
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness and gastrointestinal tolerability during conversion and titration with once-daily OROS® hydromorphone extended release in opioid-tolerant patients with chronic low back pain.
Hale ME; Nalamachu SR; Khan A; Kutch M
J Pain Res; 2013; 6():319-29. PubMed ID: 23658495
[TBL] [Abstract][Full Text] [Related]
40. Use of hydromorphone, with particular reference to the OROS formulation, in the elderly.
Lussier D; Richarz U; Finco G
Drugs Aging; 2010 Apr; 27(4):327-35. PubMed ID: 20361803
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
